Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Thalassemia: Overview of Pathophysiology and Risk for Malignancies

Ali Taher

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

2024 Updates on Myeloproliferative Neoplasms, PV, and ET

Integrity CE

A. Tefferi

Diagnosis of ITP (Including Differential Diagnosis) and Disease Mana…

Drew Provan

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

Experts Discuss Pros and Cons of Treatment Approaches in PV

BMFcases

T. Bat, A. Tefferi

Diagnosis and Prognosis in PV: Utility of BM Biopsy, Clinical Findin…

BMFcases

T. Bat, A. Tefferi

2024 Updates in PV/ET

University of Colorado Division of Hematology

B. McMahon

The Role of Complement in Disease: Focus on PNH, aHUS, CAPS, and CAD

Ilene Weitz

PV and Its Relationship to Acute Leukemia

16th International Congress on Myeloproliferative Neoplasms

J. Spivak

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

Selection of JAK1/2 Inhibitors for Primary Myelofibrosis

16th International Congress on Myeloproliferative Neoplasms

A. Gerds

Defining Risk of Progression in CHIP/CCUS: A Pathologists' Perspecti…

16th International Congress on Myeloproliferative Neoplasms

R. Hasserjian

Evolving Treatment Landscape in ITP

Robert Bird

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

Management of MF After Ruxolitinib Failure

Vanderbilt University Medical Center (VUMC)

A. Kishtagari